KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other financing activities (2016 - 2025)

Historic Other financing activities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $40.0 million.

  • Teva Pharmaceutical Industries' Other financing activities rose 26363.64% to $40.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $42.0 million, marking a year-over-year increase of 62500.0%. This contributed to the annual value of $41.0 million for FY2025, which is 61250.0% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Other financing activities stood at $40.0 million, which was up 26363.64% from -$2.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Other financing activities high stood at $40.0 million for Q4 2025, and its period low was -$76.0 million during Q3 2023.
  • Moreover, its 5-year median value for Other financing activities was -$2.0 million (2021), whereas its average is -$15.9 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Other financing activities crashed by 410000.0% in 2022, and later soared by 26363.64% in 2025.
  • Teva Pharmaceutical Industries' Other financing activities (Quarter) stood at -$1.0 million in 2021, then tumbled by 200.0% to -$3.0 million in 2022, then tumbled by 2433.33% to -$76.0 million in 2023, then skyrocketed by 114.47% to $11.0 million in 2024, then surged by 263.64% to $40.0 million in 2025.
  • Its Other financing activities was $40.0 million in Q4 2025, compared to -$2.0 million in Q3 2025 and $1.0 million in Q2 2025.